Results 91 to 100 of about 540,096 (367)

Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review

, 2018
Youting Bao,1,2,* Zhichao Liu,2,3,* Meiying Guo,2,4 Butuo Li,2,5 Xindong Sun,2 Linlin Wang2 1Department of Oncology, Clinical College, Weifang Medical University, Weifang 261053, 2Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to ...
Guo M, Liu Z, Bao Y, Li B, Sun X, Wang L
core  

Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration

, 2013
The therapeutic potential of epigallocatechin gallate, a green tea polyphenol with anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration.
McConnell, G., Dufès, C., Dufès, Christine, Lemarié, Fanny, Amor, R., Chang, Chun Wai, Norris, G., Tetley, L., Tetley, Laurence, Blatchford, David, Lemarié, F., Chang, C.W., Norris, Greg, McConnell, Gail, Amor, Rumelo, Blatchford, D.R.   +15 more
core   +1 more source

Role of Bcl-3 in solid tumors [PDF]

, 2011
Bcl-3 is an established oncogene in hematologic malignancies, such as B-cell chronic lymphocytic leukemias. Nevertheless, recent research has shown that it also participates in progression of diverse solid tumors.
Vilma Maldonado, Maldonado Vilma, Melendez-Zajgla Jorge, Jorge Melendez-Zajgla   +3 more
core   +1 more source

Microenvironment of Solid Tumors

Frontiers in Bioscience-Landmark
The tumor microenvironment (TME) plays a fundamental role in tumor progression. Cancer cells interact with their surroundings to establish a supportive niche through structural changes and paracrine signaling. Cells around transformed tumor cells contribute to cancer development, while infiltrating immune cells in this aggressive TME often become ...
Nickolai A. Barlev, Mikhail I. Shakhparonov, Nikolay B. Pestov, Tatyana V. Korneenko   +3 more
openaire   +2 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

High-dose chemotherapy for germ cell tumors: do we have a model?

, 2015
INTRODUCTION: Since the late nineties, the intensification of chemotherapy doses with hematopoietic stem cell rescue held promise for patients with advanced and poor prognosis germ cell tumors (GCTs).
Farè E., Pedrazzoli P., Lanza F., Martino M., Necchi A., Rosti G., European Society for Blood and Marrow Transplantation, Solid Tumors Working Parti (EBMT-STWP) and the Italian Germ Cell Cancer Group (IGG)   +6 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

, 2019
Esteban Cruz, Veysel KayserSchool of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaAbstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors.
Kayser V, Cruz E
core  

Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors [PDF]

, 2023
Philipp Knopf, Dimitri Stowbur, Sabrina H. L. Hoffmann, Natalie Hermann, Andreas Maurer, Valentina Bucher, Marilena Poxleitner, Bredi Tako, Dominik Sonanini, Balaji Krishnamachary, Sanhita Sinharay, Birgit Fehrenbacher, Irene González-Menéndez, Felix Reckmann, David Bomze, Lukas Flatz, Daniela Kramer, Martin Schaller, Stephan Forchhammer, Zaver M. Bhujwalla, Leticia Quintanilla‐Martínez, Klaus Schulze‐Osthoff, Mark D. Pagel, Marieke F. Fransen, Martin Röcken, André F. Martins, Bernd J. Pichler, Kamran Ghoreschi, Manfred Kneilling   +28 more
openalex   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source